Cover Image
Market Research Report

Myocardial Ischemia Market: By Diagnosis (Cardiac CT Scan, ECG, Nuclear Scan, Others), By Treatment (Medications, Surgery Methods, Others), & By Geography (Europe, Asia Pacific, North America, Rest of the World)-Forecast 2019-2024

Published by IndustryARC Product code 422372
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Myocardial Ischemia Market: By Diagnosis (Cardiac CT Scan, ECG, Nuclear Scan, Others), By Treatment (Medications, Surgery Methods, Others), & By Geography (Europe, Asia Pacific, North America, Rest of the World)-Forecast 2019-2024
Published: December 25, 2018 Content info:
Description

Myocardial Ischemia happens where there is an insufficient flow of blood in heart muscles. Some symptoms are, the heart is not able to pump oxygenated blood and other vital nutrients to the body efficiently and finally leads to destruction of the heart muscles. Blockage of an artery etc. Globally, prevalence of various heart-related diseases, and growing awareness of the population are the prime growth drivers of global Myocardial Ischemia market. In addition, increase in adoption of Myocardial Ischemia treatments in emerging economies such as China, India and others, will create new opportunities for global Myocardial Ischemia market. However, higher cost of the research and development, and limited healthcare infrastructure are the key restraints for global Myocardial Ischemia market.

Geographically North America dominated global Myocardial Ischemia market, followed by Europe. Europe is projected to have fastest growth, owing to increase in the prevalence of various heart-related diseases, and growing awareness of the population about cardiovascular diseases. Asia Pacific is developing rapidly and is considered to be as one of the most promising markets for the augmentation of myocardial ischemia market. The factors which will contribute towards the growth of this market in Asia Pacific are presence of emerging economies, constantly changing lifestyles of people which have accelerated the prevalence of serious heart ailments, and better healthcare infrastructures.

This report identifies the global Myocardial Ischemia market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global Myocardial Ischemia market.

This report segments global Myocardial Ischemia market on the basis of diagnosis, treatment, and regional market as follows:

Myocardial Ischemia Market, By Diagnosis: Cardiac CT Scan. ECG, Nuclear Scan, and Others

The report has focused study on Myocardial Ischemia market on the basis of treatment such as: Medications, Surgery Methods, and Others

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the Myocardial Ischemia market. Some of the major companies' profiles in detail are as follows:

Baxter International, Inc

Boston Scientific Corporation

Cardium Therapeutics, Inc

ViroMed Co. Ltd

Atrium Medical Corporation

Table of Contents

Table of Contents

1. Myocardial Ischemia Market - Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Myocardial Ischemia Market- Market Forces

  • 4.1. Drivers
    • 4.1.1. Prevalence of various heart-related diseases
    • 4.1.2. Growing awareness of the population
  • 4.2. Restraints
    • 4.2.1. Limited health Infrastructure
  • 4.3. Opportunities
    • 4.3.1. Emerging economies
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Myocardial Ischemia Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Myocardial Ischemia Market, By Diagnosis

  • 6.1. Cardiac CT Scan
  • 6.2. Electrocardiogram
  • 6.3. Nuclear Scan
  • 6.4. Coronary Angiography
  • 6.5. Holter Monitoring

7. Myocardial Ischemia Market, By Treatment

  • 7.1. Medications
  • 7.2. Surgery Methods

8. Myocardial Ischemia Market, By Geography

  • 8.1. Europe
    • 8.1.1. Germany
    • 8.1.2. France
    • 8.1.3. Italy
    • 8.1.4. Spain
    • 8.1.5. Russia
    • 8.1.6. U.K.
    • 8.1.7. Rest of Europe
  • 8.2. Asia Pacific
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. South Korea
    • 8.2.5. Rest of Asia-Pacific
  • 8.3. North America
    • 8.3.1. U.S.
    • 8.3.2. Canada
    • 8.3.3. Mexico
  • 8.4. Rest of the World (RoW)
    • 8.4.1. Brazil
    • 8.4.2. Rest of RoW

9. Myocardial Ischemia - Market Entropy

  • 9.1. Expansion
  • 9.2. Technological Developments
  • 9.3. Merger & Acquisitions, and Joint Ventures
  • 9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 10.1. Baxter International, Inc
  • 10.2. Boston Scientific Corporation
  • 10.3. Cardium Therapeutics, Inc
  • 10.4. ViroMed Co. Ltd
  • 10.5. Atrium Medical Corporation
  • 10.6. Vasade Biosciences, Inc.
  • 10.7. Sanofi
  • 10.8. Pfizer Inc
  • 10.9. Medicure Inc
  • 10.10. Terumo Interventional Systems Inc.

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Bibliography
  • 11.5. Compilation of Expert Insights
  • 11.6. Disclaimer
Back to Top